$QBIO has become the target of big pharma because of their innovative glaucoma treatment in a space that hasn't had much innovation in 20 years. https://www.theglobeandmail.com/investing/markets/stocks/QBIO/pressreleases/462127/ This is a low float stock that is tightly held and it has multiple upcoming catalysts according to the CEO : [yt]R302O-Ox0Ko[/yt]